Model for End-Stage Liver Disease

Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis

Retrieved on: 
Tuesday, August 15, 2023
Drug development, NASH, Hepatocellular carcinoma, Liver disease, GGT, COVID-19, Food and Drug Administration, Cancer, Cirrhosis, FVC, Cough, LOXL2, Model for End-Stage Liver Disease, Fibrosis, Vital capacity, Patient, Investment, Periodic breathing, ALT, Mortality, FDA, IPF, Death, AST, Idiopathic pulmonary fibrosis, Food, Safety, Pharmaceutical industry, Medical device, Medicine, MELD, Hepatology, Galecto Biotech

Based on the results of the GALACTIC-1 trial, Galecto plans to discontinue development of GB0139.

Key Points: 
  • Based on the results of the GALACTIC-1 trial, Galecto plans to discontinue development of GB0139.
  • “We are very disappointed that the GALACTIC-1 results do not support the continued development of GB0139 as a new treatment for IPF,” said Hans Schambye, President and Chief Executive Officer of Galecto.
  • The trial compared treatment with the inhaled 3 mg dose of GB0139 to placebo (randomized 2:1) over 52 weeks.
  • Galecto previously announced topline results from its Phase 1b/2a GULLIVER-2 trial of GB1211, its orally available galectin-3 inhibitor, for the treatment of decompensated cirrhosis.

LyGenesis and Imagine Pharma Announce Joint Research Collaboration to Develop Novel Cell Therapies for Patients with Type 1 Diabetes

Retrieved on: 
Tuesday, April 11, 2023
Pharma, Diabetes, CMO, Model for End-Stage Liver Disease, Doctor of Philosophy, Regenerative medicine, MD, Patient, American Indian Public High School, Entrepreneurship, United, Therapy, Pharmaceutical industry, T1D

PITTSBURGH, April 11, 2023 /PRNewswire/ -- LyGenesis, Inc., a clinical-stage biotechnology company developing allogenic cell therapies for large unmet needs, and Imagine Pharma, a biotechnology company focused on the development of its novel polypeptide (IMG-1) across three distinct platforms: Oral Delivery, Therapeutics, and Regenerative Medicine, announced today that they have entered into a joint research collaboration to develop novel cell therapies for patients with type 1 diabetes. The research collaboration will leverage Imagine Pharma's Type 1 Diabetes Activated Islet Progenitor Cells (T1D AIPCs) and LyGenesis' allogeneic cell therapy platform to develop therapies for type 1 diabetes.

Key Points: 
  • PITTSBURGH, April 11, 2023 /PRNewswire/ -- LyGenesis, Inc., a clinical-stage biotechnology company developing allogenic cell therapies for large unmet needs, and Imagine Pharma , a biotechnology company focused on the development of its novel polypeptide (IMG-1) across three distinct platforms: Oral Delivery, Therapeutics, and Regenerative Medicine, announced today that they have entered into a joint research collaboration to develop novel cell therapies for patients with type 1 diabetes.
  • The research collaboration will leverage Imagine Pharma's Type 1 Diabetes Activated Islet Progenitor Cells (T1D AIPCs) and LyGenesis' allogeneic cell therapy platform to develop therapies for type 1 diabetes.
  • Type 1 diabetes affects 1.45 million people in the United States with about 64,000 new diagnoses every year.
  • "We envision that our novel cell population of AIPCs, used in conjunction with LyGenesis' cell therapy platform, holds breakthrough potential for the treatment of type 1 diabetes," said Ngoc Thai, MD, PhD, Founder, CMO and Co-CEO at Imagine Pharma.

Apollo Hospitals Group Completes 500 Pediatric Liver Transplants

Retrieved on: 
Monday, March 13, 2023
Organ transplantation, Liver disease, Consultant, Apollo Hospitals, World Federation of Associations of Pediatric Surgeons, Liver transplantation, Intensivist, Physician, Nursing, Surgeon, Kidney disease, Group medical practice in the United States, Kidney transplantation, Model for End-Stage Liver Disease, Gastrointestinal tract, Pancreas, Transplant, ABO, Patient, CIS, Family, Heart, Lung transplantation, Health, Liver failure, Dentistry, Gastroenterology, Certified Registered Nurse Anesthetist, Nephrology

Today the Apollo Hospitals Group announced the successful completion of 500 pediatric liver transplants.

Key Points: 
  • Today the Apollo Hospitals Group announced the successful completion of 500 pediatric liver transplants.
  • Dr. Prathap C Reddy, Founder Chairman, Apollo Hospitals Group, said, "India is emerging as a world leader in organ transplantation.
  • This milestone further reflects our commitment to advancing pediatric liver transplantation and providing the best possible care to our patients.
  • The Apollo Liver Transplant Program is now consistently performing close to 50 pediatric liver transplants a year, a number only a handful of centres in the world have achieved."

Apollo Hospitals Group Completes 500 Pediatric Liver Transplants

Retrieved on: 
Monday, March 13, 2023
Organ transplantation, Liver disease, Consultant, Apollo Hospitals, World Federation of Associations of Pediatric Surgeons, Liver transplantation, Intensivist, Physician, Nursing, Surgeon, Kidney disease, Group medical practice in the United States, Kidney transplantation, Model for End-Stage Liver Disease, Gastrointestinal tract, Pancreas, Transplant, ABO, Patient, CIS, Family, Heart, Lung transplantation, Health, Liver failure, Dentistry, Gastroenterology, Certified Registered Nurse Anesthetist, Nephrology

Today the Apollo Hospitals Group announced the successful completion of 500 pediatric liver transplants.

Key Points: 
  • Today the Apollo Hospitals Group announced the successful completion of 500 pediatric liver transplants.
  • Dr. Prathap C Reddy, Founder Chairman, Apollo Hospitals Group, said, "India is emerging as a world leader in organ transplantation.
  • This milestone further reflects our commitment to advancing pediatric liver transplantation and providing the best possible care to our patients.
  • The Apollo Liver Transplant Program is now consistently performing close to 50 pediatric liver transplants a year, a number only a handful of centres in the world have achieved."

Chronic Lymphocytic Leukemia (CLL) Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031

Retrieved on: 
Monday, February 20, 2023
PBF, Population Health Management, Clinical trial, WMH, Epidemiology, Chronic lymphocytic leukemia, Model for End-Stage Liver Disease, Patient, POLI, Pharmaceutical industry, CLL

These sales forecast extrapolations leverage data on pharmaceutical sales and drug availability from World Markets Healthcare (WMH) and PharmOnline International (POLI) Price Intelligence databases.

Key Points: 
  • These sales forecast extrapolations leverage data on pharmaceutical sales and drug availability from World Markets Healthcare (WMH) and PharmOnline International (POLI) Price Intelligence databases.
  • The report also analyzes the clinical and commercial landscapes of CLL, with pricing assumptions based on currently marketed products by class of cell therapies, accompanied by a transparent forecast methodology.
  • Additionally, the report evaluates indication-specific unmet needs and competitive assessments and identifies key future players in the cell therapy market.
  • Cell therapy is a promising modality for treating CLL and can provide the most value by demonstrating long-term disease control in high-risk and young patients.

Madrigal Pharmaceuticals Initiates the MAESTRO-NASH Outcomes Study Evaluating Resmetirom for the Treatment of Patients with Compensated NASH Cirrhosis

Retrieved on: 
Wednesday, August 31, 2022
Mortality, Hepatic encephalopathy, NASDAQ, Model for End-Stage Liver Disease, Incidence, Ascites, GLOBE, Therapy, NASH, Fatty liver disease, MELD, Patient, Pharmaceutical industry, Dietary supplement, Medical imaging

MAESTRO-NASH Outcomes is a Phase 3, double-blind, randomized, placebo-controlled study that will noninvasively measure progression to liver decompensation events in approximately 700 patients with compensated NASH cirrhosis.

Key Points: 
  • MAESTRO-NASH Outcomes is a Phase 3, double-blind, randomized, placebo-controlled study that will noninvasively measure progression to liver decompensation events in approximately 700 patients with compensated NASH cirrhosis.
  • Paul Friedman, M.D., Chief Executive Officer of Madrigal, stated, The MAESTRO-NASH Outcomes study is designed to address an urgent unmet need for patients and expand the long-term commercial opportunity for resmetirom.
  • Positive results from this study could support full approval in the noncirrhotic population and potential for approval in an additional indication in patients with well-compensated NASH cirrhosis.
  • In addition, this study has the potential to support an additional indication for resmetirom in patients with well-compensated NASH cirrhosis.

iTolerance and LyGenesis Announce a Joint Research Collaboration to Regrow Functioning, Ectopic Livers Without the Need for Immune Suppression

Retrieved on: 
Thursday, June 30, 2022
Model for End-Stage Liver Disease, FDA, Liver failure, Patient, Ageing, Protein, B cell, Research, CRISPR, Immunosuppression, Pancreas, Company, Metabolism, Hormone, SA, Hepatocyte, Bioreactor, Kidney, Lymph, Good manufacturing practice, Regenerative medicine, Type 1, Technology, Fas ligand, Blood, Entrepreneurship, Animal, Immune tolerance, Time, Organoid, Pharmaceutical industry, Vaccine

The joint research collaboration has generated in vitro data with iTOL-201 and is now progressing toward small animal proof of concept work to evaluate the combined technology's potential to produce ectopic livers capable of rescuing the animals from otherwise fatal liver disease without the need for immune suppression.

Key Points: 
  • The joint research collaboration has generated in vitro data with iTOL-201 and is now progressing toward small animal proof of concept work to evaluate the combined technology's potential to produce ectopic livers capable of rescuing the animals from otherwise fatal liver disease without the need for immune suppression.
  • iTolerance is an early-stage privately held regenerative medicine company developing technology to enable tissue, organoid or cell therapy without the need for life-long immunosuppression.
  • Utilizing iTOL-100 to induce local immune tolerance, iTOL-102 has the potential to be a cure for Type 1 Diabetes without the need for life-long immunosuppression.
  • LyGenesis is a clinical-stage biotechnology company whose cell therapies use patients' lymph nodes as bioreactors to regrow functioning ectopic organs.

Ochre Bio Launches ‘Liver ICU’ in the United States to Evaluate Effects of RNA Therapies on Human Liver Performance

Retrieved on: 
Wednesday, May 11, 2022
Biotechnology, Pharmaceutical, Health, Other Health, Laboratory, Ochre, CSO, Bio, Transplant, Chronic liver disease, RNA, Liver disease, Yale University, Institute of Liver and Biliary Sciences, Doctor of Philosophy, Patient, Partnership, Organization, Cirrhosis, FDA, Therapy, Genomics, Yale School of Medicine, Science, Physiology, Model for End-Stage Liver Disease, LifeSharers, Organ transplantation, Assistant, Liver transplantation, CEO, New England Biolabs, Research, Dietary supplement, Medical imaging, Dentistry

Ochre Bio , a biotech company developing RNA medicines for chronic liver diseases, announced today the launch of their Liver ICU.

Key Points: 
  • Ochre Bio , a biotech company developing RNA medicines for chronic liver diseases, announced today the launch of their Liver ICU.
  • Housed in BioLabs@NYULangone, a biopharma incubator in New York City, this research site will evaluate the efficacy of new RNA therapeutics on whole human livers maintained on machines.
  • This site is a part of a network of three leading liver perfusion research sites across the US.
  • Ochre Bio is a biotechnology company developing RNA therapies for chronic liver diseases.

First Patient Recruited for Multi-Year Collaborative Primary Sclerosing Cholangitis (PSC) Pediatric Study Using Perspectum’s Imaging Technology to Help Predict Disease Progression and Guide Patient Management

Retrieved on: 
Friday, January 28, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Hospitals, Clinical Trials, Diagnosis, Primary sclerosing cholangitis, PSC, Risk, Patient, Cirrhosis, Digestive, Liver disease, Immune system, Child, Organization, HIV disease progression rates, MRCP, Inflammatory bowel disease, NIDDK, Ulcerative colitis, Physician, Liver, National, Bile, Liver transplantation, UC, Twitter, Model for End-Stage Liver Disease, Research, Clinical trial, Autoimmune hepatitis, Kidney, Natural history, Cancer, Nursing, Laboratory, AIH, Partnership, MRI, Fibrosis, Biomarker, Precision medicine, Cincinnati Children's Hospital Medical Center, SeriousFun Children's Network, Health, Network, Ageing, Stenosis, Biliary injury, Colorectal cancer, IBD, Nation, Genetics, National Institute, United Kingdom, Medical imaging, MD

Perspectum announced recruitment of the first patient in a multi-center collaborative study to characterize Primary Sclerosing Cholangitis in children, Prospective Observational Study of Primary Sclerosing Cholangitis (PSC) in Children .

Key Points: 
  • Perspectum announced recruitment of the first patient in a multi-center collaborative study to characterize Primary Sclerosing Cholangitis in children, Prospective Observational Study of Primary Sclerosing Cholangitis (PSC) in Children .
  • This 10-year collaborative study includes 12 geographically-diverse childrens hospitals in the United States and one Canadian childrens hospital.
  • Perspectums quantitative imaging tool, MRCP+, that uses computational techniques to enhance conventional magnetic resonance cholangiopancreatography (MRCP) images , will provide biliary tree measurements to evaluate biliary injury and monitor disease progression.
  • Comparing these results to those from other imaging modalities will enable the study partners to determine which biomarkers of fibrosis and biliary injury can best predict disease progression and guide patient management.

At-Risk Shelter Dogs Given Another Chance at Life with Veterans and Inmates through Marley's Mutts ® Pawsitive Change Program and Hounds and Heroes Emotional Support Dog Program Partnership

Retrieved on: 
Thursday, September 23, 2021
Adoption, Los Angeles, Partnership, Mutts, NBA, Super Bowl, PR, Veteran, 1972 NBA Finals, ESA, Diathesis–stress model, NFL, Super Bowl counterprogramming, Model for End-Stage Liver Disease, Dog, Program, Life, Love, Emotional support animal, Hounds for Heroes, Organization, Animal, Hunting

LOS ANGELES, Sept. 23, 2021 /PRNewswire/ -- Hounds and Heroes and Marley's Mutts Dog Rescue announce a partnership within the initiative, Pawsitive Change Prison Program.

Key Points: 
  • LOS ANGELES, Sept. 23, 2021 /PRNewswire/ -- Hounds and Heroes and Marley's Mutts Dog Rescue announce a partnership within the initiative, Pawsitive Change Prison Program.
  • The collaboration between the two organizations will pair at-risk shelter dogs with incarcerated individuals and veterans through the Pawsitive Change Program, co-founded by Zach Skow, Founder and PR Director of Marley's Mutts.
  • Select individuals of California state and federal prisons will participate in the Pawsitive Change Program.
  • Graduates will earn their Canine Good Citizen certificate to move on to assessment for the Emotional Support Animal Program with Hounds and Heroes will making final evaluations.